Abstract
Cyclic dinucleotides (CDNs) are now established as master regulators of bacterial physiology (cyclic di-GMP, cyclic di-AMP, 3′3′-cGAMP) and immune function (bacterial cyclic dinucleotides and host’s 2′3′-cGAMP). Metabolic enzymes that modulate the concentrations of CDNs and/or effector proteins or nucleic acids that bind to these second messengers are potential therapeutic targets for the development of antibiofilm, antivirulence, and immunomodulatory agents. Here, we discuss some of the recent advances in the development of small molecule regulators of cyclic di-GMP, cyclic di-AMP, and cGAMP signaling.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
